Deciphera Pharmaceuticals LLC (Deciphera)

Oncology Corporate Profile

HQ Location

643 Massachusetts, Suite 200
Lawrence, KS 66044

Company Description

Deciphera Pharmaceuticals, LLC is a clinical-stage biotechnology company developing improved kinase inhibitor treatments for cancer. Deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. With business and development operations based in Boston, and dedicated research capabilities in close proximity to the University of Kansas, Deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
rebastinib / DCC-2036BCR-ABL kinase inhibitorAcute Lymphocytic Leukemia (ALL)IEli Lilly
rebastinib / DCC-2036BCR-ABL kinase inhibitorChronic Myelogenous Leukemia (CML)IEli Lilly
DCC-2618cKIT inhibitorGastrointestinal Stromal Tumors (GIST)I
DCC-2618cKIT inhibitorVarious cancer typesI
DCC-2701multitarget inhibitor of VEGFR-2, c-Met & Tie2Various cancer typesI
DP-4978pan-RAF kinase inhibitorVarious cancer typesPreclinicalEli Lilly
DCC-2721cMet inhibitorVarious cancer typesPreclinical

View additional information on product candidates here »


Recent News Headlines

There are no news items to display